Vaccine holds hope of preventing antibiotic resistant skin infections

In this electron micrograph, a white blood cell eats an antibiotic resistant bacteria called methicillin-resistant Staphylococcus aureus, or MRSA. Credit: National Institute of Allergy and Infectious Diseases

In the U.S. and around the globe, skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus (MRSA) continue to endanger the health and lives of patients and otherwise healthy individuals.

Treatment is difficult because MRSA is resistant to many antibiotics, and the infections can recur, placing family members and other close contacts at risk of infection.

A study reported online today in the Proceedings of the National Academy of Sciences USA holds new hope for preventing or reducing the severity of infections caused by the "superbug" MRSA. In the study, infectious disease specialists at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) reported that a new investigational vaccine, NDV-3, employing the recombinant protein Als3, can mobilize the immune system to fight off MRSA skin infections in an experimental model. The researchers found the vaccine works by enhancing molecular and cellular immune defenses of the skin in response to MRSA and other S. aureus bacteria in disease models.

"This is the first published study to demonstrate the effectiveness of a cross-kingdom recombinant vaccine against MRSA skin infections," said Dr. Michael R. Yeaman, lead author of the study. "NDV-3 is unique as it is the first vaccine to demonstrate it can be effective in protecting against infections caused by both S. aureus and the fungus Candida albicans. NDV-3 represents a novel approach to vaccine design."

The research team found the NDV-3 vaccine reduced severity and progression of in a model of the MRSA-caused disease, and prevented MRSA invasion from the skin to deeper tissues. The team said these findings support further evaluation of NDV-3 to address disease caused by S. aureus in humans. NDV-3 has been licensed to NovaDigm Therapeutics, Inc. and has already been found to be well-tolerated and capable of producing immune responses in human clinical trials similar to those observed to be effective in the present disease model.

A vaccine to prevent or minimize infections caused by S. aureus could significantly improve public health because this pathogen is the leading cause of skin and skin structure infections, which can lead to life-threatening blood infections. It is also a significant cause of surgical or traumatic wound infections, diabetic skin lesions, and pneumonia or endocarditis.

"Up to one-third of patients diagnosed with invasive S. aureus infections die, accounting for more annual deaths than HIV, tuberculosis and viral hepatitis combined," Dr. Yeaman said. "A vaccine that could prevent or lessen the severity of MRSA infections would be a significant advance in patient care and public health."

Explore further

Using wash cloths in jails shows promise for reducing costly infections

More information: Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection, PNAS,
Citation: Vaccine holds hope of preventing antibiotic resistant skin infections (2014, December 8) retrieved 6 May 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments